{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vitamin+K+antagonists", "query": { "intervention": "vitamin K antagonists" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vitamin+K+antagonists&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T11:22:53.979Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00440193", "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin followed by VKA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3449, "start_date": "2007-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2014-02-27", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Redlands", "state": "California" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440193" }, { "nct_id": "NCT01684423", "title": "Oral Rivaroxaban in Children With Venous Thrombosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Active comparator", "type": "DRUG" }, { "name": "Rivaroxaban (BAY59-7939) suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 64, "start_date": "2013-02-19", "completion_date": "2016-09-01", "has_results": true, "last_update_posted_date": "2017-09-21", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01684423" }, { "nct_id": "NCT04045665", "title": "Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Bleeding" ], "interventions": [ { "name": "Antiplatelet-only strategy", "type": "DRUG" }, { "name": "Oral Anticoagulant plus background antiplatelet therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3200, "start_date": "2019-12-13", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04045665" }, { "nct_id": "NCT02464969", "title": "Apixaban for the Acute Treatment of Venous Thromboembolism in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Days to 17 Years" }, "enrollment_count": 229, "start_date": "2015-11-22", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 84, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464969" }, { "nct_id": "NCT00252005", "title": "Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Deep-Vein Thrombosis" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 520, "start_date": "2005-11", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2010-03-02", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 5, "location_summary": "Albuquerque, New Mexico • Chapel Hill, North Carolina • San Antonio, Texas + 2 more", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fredericksburg", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00252005" }, { "nct_id": "NCT02740335", "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Significant Bleeding Risk" ], "interventions": [ { "name": "Octaplex", "type": "DRUG" }, { "name": "Beriplex P/N (Kcentra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2017-06-08", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2023-03-08", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 22, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740335" }, { "nct_id": "NCT04226547", "title": "Amplatzer Amulet LAAO vs. NOAC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Bleeding" ], "interventions": [ { "name": "Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)", "type": "DEVICE" }, { "name": "Non-Vitamin K Oral Antagonists", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2650, "start_date": "2020-07-07", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04226547" }, { "nct_id": "NCT00062803", "title": "SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Embolism" ], "interventions": [ { "name": "SR34006", "type": "DRUG" }, { "name": "(LMW)heparin", "type": "DRUG" }, { "name": "Warfarin VKA", "type": "DRUG" }, { "name": "Acenocoumarol VKA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2009-04-29", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 54, "location_summary": "Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Bay Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062803" }, { "nct_id": "NCT02072434", "title": "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2199, "start_date": "2014-03-25", "completion_date": "2016-02-03", "has_results": true, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072434" }, { "nct_id": "NCT01729871", "title": "A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "rivaroxaban", "type": "DRUG" }, { "name": "uninterrupted vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2013-02", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-09-26T11:22:53.979Z", "location_count": 24, "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729871" } ] }